Nuvation Bio NUVB
NYSE NUVB
$4.30 +0.11 (+2.50%)
As of: Nov 11, 2026 · 10:31 AM EST

Nuvation Bio (NUVB) Non-Current Deferred Revenue (2024 - 2026)

Updated

Nuvation Bio's Non-Current Deffered Revenue was $151.12 million in Q2 2026, up 5.8% from $142.78 million a year earlier but down 0.5% from the prior quarter.

Analysis

Nuvation Bio (NUVB) Non-Current Deferred Revenue (2024 - 2026) Analysis & Trends

At the end of FY2025, Non-Current Deffered Revenue at Nuvation Bio came in at $145.82 million.

  • Quarterly Non-Current Deffered Revenue has moved between $7.94 million (Q3 2024) and $151.89 million (Q1 2026) over five years.
  • Per Business Quant data, NUVB's Non-Current Deffered Revenue in the three quarters before Q2 2026 was $151.89 million (Q1 2026), $145.82 million (Q4 2025) and $144.62 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Nuvation Bio 1.46 Bn -931.95 Mn 42.84 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 151.52 Mn
Jun 30, 2026 151.12 Mn
Mar 31, 2026 151.89 Mn
Dec 31, 2025 145.82 Mn
Sep 30, 2025 144.62 Mn
Jun 30, 2025 142.78 Mn
Mar 31, 2025 13.61 Mn
Sep 30, 2024 7.94 Mn
Jun 30, 2024 9.16 Mn
API Access

Nuvation Bio Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=NUVB&period=max&api_key=YOUR_API_KEY